UCART123v1.2

· Cellectis S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UCART123v1.2, covering 2025-08-07 to 2025-08-07. Get the full timeline:

Most recent: Clinical Trial Update: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

See pricing